A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy

Ella S Y Park; Guilherme Rabinowits; Ole-Petter R Hamnvik; Linda R Dagi

doi:10.1016/j.jaapos.2018.01.006

A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy

J AAPOS. 2018 Aug;22(4):310-312. doi: 10.1016/j.jaapos.2018.01.006. Epub 2018 Apr 4.

Authors

Ella S Y Park¹, Guilherme Rabinowits², Ole-Petter R Hamnvik³, Linda R Dagi⁴

Affiliations

¹ Yonsei University College of Medicine, Seoul, South Korea.
² Medical Oncology Department, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁴ Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: Linda.Dagi@childrens.harvard.edu.

PMID: 29626663
DOI: 10.1016/j.jaapos.2018.01.006

Abstract

We present the first reported case of Graves' orbitopathy induced by pembrolizumab, a new FDA-approved drug used for the treatment of multiple refractory solid tumors and classic Hodgkin lymphoma. Pembrolizumab elicits T-lymphocyte proliferation; we suspect that thyroid eye disease may result in some cases.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Graves Ophthalmopathy / chemically induced*
Humans
Male
Middle Aged

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab